CASP8 promoter polymorphism, mRNA expression and risk of prostate cancer among Chinese men

Guangbo Fu, Jialin Tang, Meilin Wang, Chao Qin, Fu Yan, Qi Ding, Changjun Yin, Xinru Wang, Zhengdong Zhang

1Key Laboratory of Reproductive Medicine, School of Public Health, Institute of Toxicology, Nanjing Medical University, Nanjing, Jiangsu 210029, China
2Department of Urology, Huai-An First Affiliated Hospital, Nanjing Medical University, Huai-An, Jiangsu 211000, China
3Jiangsu Key Laboratory of Cancer Biomarkers, Prevention & Treatment, Cancer Center, Nanjing Medical University, Nanjing, Jiangsu 210029, China
4Department of Molecular & Genetic Toxicology, School of Public Health, Cancer Center, Nanjing Medical University, Nanjing, Jiangsu 210029, China
5Department of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China

Received 01 March 2011, Accepted 07 March 2011

Abstract

Caspase-8 (CASP8) plays a key role in apoptosis. We examined by genotyping whether the -652 six-nucleotide insertion-deletion (6N ins/del) polymorphism in the CASP8 promoter region was associated with prostate cancer risk in a hospital-based case-control study of 406 Chinese prostate cancer patients and 408 age-matched cancer-free controls. Additionally, 23 prostate cancer tissues were analyzed for CASP8 mRNA expression. We found a significantly decreased prostate cancer risk for the 6N ins/del genotype [adjusted odds ratio (OR)=0.68; 95% confidence interval (CI)=0.51-0.92] and del/del genotype (OR=0.34; 95% CI=0.19-0.63) compared with the ins/ins genotype. The 6N del allele was associated dose-dependently with decreased prostate cancer risk (P<0.001). RT-PCR showed that individuals with the 6N del allele had lower CASP8 mRNA levels than those with the ins/ins genotype (P = 0.024). These findings suggested that the CASP8-652 6N ins/del polymorphism may affect the susceptibility to prostate cancer and reduce prostate cancer risk among Chinese men.

Keywords: caspase-8, promoter polymorphism, genetic variation, prostate cancer

INTRODUCTION

Prostate cancer is the most common diagnosed malignant cancer and the second leading cause of cancer deaths in men in the United States, with an estimated 192,280 new cases and 27,360 deaths in 2009[1]. The well-known risk factors for prostate cancer are age, family history of prostate cancer and ethnicity[2]. Ethnic differences in the incidence of prostate cancer have been well established, with the highest rates in...
Western countries and lowest in Asia countries\cite{13,14}. Although the prostate cancer rate is lower in China than that in Western countries, the incidence of prostate cancer has increased rapidly among Chinese men over the recent years\cite{15}. As shown in previous studies, both genetic and environmental factors are involved in the development of prostate cancer\cite{16-18}.

Apoptosis is an essential protective mechanism against excessive cellular proliferation and malignancy\cite{19}. Cells are persistently in a balance between proliferation and apoptosis, and dysfunction of this balance may increase the risk of cancer\cite{20}. Studies have reported that caspases are at the crossroads of immune cell life and death, and their aberrant expressions or activities are associated with many pathological conditions, including cancer\cite{21}. Caspase-8 (CASP8) is a crucial member of the caspase family in the apoptotic process\cite{22}. Therefore, genetic variants in CASP8 may disturb the function of CASP8 and then affect the execution of apoptosis, thus contributing to either the development or progression of human cancers.

Accumulating studies have reported that two common single nucleotide polymorphisms (SNPs) in the CASP8 promoter gene, -652 6N ins/del (rs3834129) and D302H (rs1045485), were associated with risk of cancers\cite{13,15,20,21}. Studies have revealed that the polymorphism in the CASP8 coding region, D302H, was associated with reduced breast cancer risk\cite{13,15,20,21}. Study showed that histidine variant of CASP8 D302H is a protective allele for aggressive prostate cancer\cite{20}. However, the CASP8 D302H variant showed low-penetrance in Asians (minor allele frequency, MAF = 0% in Asians, MAF = 12.5% in Europeans based on the HapMap and Environmental Genome Project database), and we could not analyze the association with prostate cancer risk in this study. Sun et al\cite{20} identified that the -652 6N ins/del polymorphism in the CASP8 promoter region was associated with several types of cancer in Chinese population, and the 6N del variant decreased mRNA expression or activity by destroying a binding site for stimulatory protein (Sp1) and protected against cancers. However, Haiman et al\cite{21} showed that the CASP8 -652 6N ins/del polymorphism was not associated with risk of cancers including prostate cancer in a multiethnic cohort study. To explore the potential association between the CASP8 -652 6N ins/del polymorphism and prostate cancer risk in a Chinese population, we performed a hospital-based case-control study with 406 prostate cancer cases and 408 cancer-free controls. Meanwhile, we evaluated the relationship between CASP8 mRNA expression and the -652 6N ins/del genotypes in prostate cancer tissue.

**MATERIALS AND METHODS**

**Study population**

This study consisted of 406 prostate cancer cases and 408 cancer-free controls. All subjects were unrelated southern Han Chinese. Cases were diagnosed with prostate cancer by needle biopsy and recruited from the First Affiliated Hospital of Nanjing Medical University between September 2003 and July 2009. The control subjects were recruited from healthy people who were seeking health care in the outpatient departments at the hospital. We used a questionnaire to obtain detailed information about demographic data and risk factors (e.g., age, race, smoking status, alcohol use, and family history of cancer) through face-to-face interviews, we frequency-matched the controls to the cases by age (±5 years).

Before recruitment, informed consent was obtained from each of the eligible subjects. Subjects who smoked one cigarette daily for more than one year were defined as ever smokers and the others as never smokers. Pack-years of smoking [(cigarettes per day \( / \text{years smoked} \times 5 \text{years})] were calculated to indicate the cumulative smoking dose. Individuals that consumed three or more alcohol drinks per week for at least six months were considered as ever drinkers, and the others were defined as never drinkers. Family history of cancer was defined as any cancer in first-degree relatives (parents, siblings, or children). Clinical stage was determined by pathologic results, pelvic computed tomography (CT), magnetic resonance image (MRI), and radio-nodule bone scans. According to the international tumor-node-metastasis (TNM) staging system for prostate cancer, the clinical stage was classified into localized and advanced stage (localized: \( T_1\), \( N_0\), \( M_0\); advanced: \( T_3\), \( N_0\), \( M_0\) or \( T_N_M_0\)). Pathologic grade was recorded based on the Gleason score. The response rate for recruitment was above 95% and 85% of the cases and controls, respectively. Each subject donated 5 mL of peripheral blood for genomic DNA extraction. Twenty-three prostate cancer tissues were collected from patients who were diagnosed with prostate cancer and underwent prostatectomy at the First Affiliated Hospital of Nanjing Medical University. All tissues were stored in liquid nitrogen. The research protocol was approved by the institutional review board of Nanjing Medical University.

**Genotyping**

According to the NCBI public SNP database, one common SNP (MAF \(5\%\) in Chinese population) rs3834129 six nucleotide insertion/deletion (6N ins/del) polymorphism was selected. The CASP8 -652
6N ins/del polymorphism was genotyped using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The primers, lengths, and restriction enzyme were described previously. Genotyping was done without knowledge of the case and control status. Polymorphism analysis was performed by two persons independently. A 10% random sample were tested for conformation, and the concordance was 100%.

**Analysis of CASP8 mRNA expression**

To further explore the correlation between the CASP8 mRNA expression and -652 6N ins/del genotypes in vivo, we extracted total RNA from 23 prostate cancer tissues with different genotypes using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. The total RNA was measured by reverse transcription-PCR (RT-PCR) and quantitative real-time PCR (qRT-PCR) (ABI Prism® 7900HT quantitative real-time PCR instrument). GAPDH was used as an internal quantitative control. The detailed methods for RT-PCR and qRT-PCR were described previously.

The primers used for amplification of CASP8 mRNA were 5’-CATCAGTCATTTGCCAGA- 3’ (sense) and 5’-GCATCTGTTTCCCCATGTGTGT- 3’ (antisense), and the primers for GAPDH were 5’-GAAATCCCCATCACTCTTCGAGG- 3’ (sense) and 5’-GAGCCCCAGCCCTCTGCATG - 3’ (antisense). Fold changes were normalized by the levels of GAPDH expression, and each assay was done in triplicate.

**Statistical analysis**

Hardy-Weinberg equilibrium (HWE) of the genotype distributions among controls was tested by a goodness-of-fit χ² test. Chi-square (Χ²) test was used to analyze the differences in variable frequency distributions, the known risk factors, CASP8 -652 6N ins/del genotypes and allele frequencies between the cases and controls. Unconditional univariate and multivariate logistic regression analysis were done to obtain the crude and adjusted odds ratios (ORs) and their 95% confidence intervals (CIs). The multivariate analysis was adjusted for age, smoking status and alcohol use. For mRNA quantitative analysis, unpaired t-test was performed to analyze the CASP8 mRNA expression levels (2^-ΔΔCT). P < 0.05 was used as the criterion of statistical significance and all tests were two-sided and analyzed by using the SAS software (Version 9.1; SAS Institute, Inc., Cary, NC, USA).

**RESULTS**

Characteristics of the study subjects

The frequency distributions of selected variables between the cases and controls are shown in Table 1. There was no difference in the distribution of age between the cases and controls (P = 0.205). However, there were more smokers (39.8% vs 49.7%, P = 0.001) and drinkers (30.0% vs 23.3%, P = 0.029) among cases than controls. Specifically, the frequency of family members with cancer from the case group was higher than the control group (28.3% vs 16.2%, P < 0.001). Among the cases, 218 (53.7%) patients were in localized stage and 188 (46.3%) were in advanced stage. The distributions of Gleason score in < 7, = 7, and > 7 subgroups among cases were 173 (42.6%), 106 (26.1%), and 127 (31.3%), respectively. Furthermore, the prostate antigen (PSA) levels were separated into two groups: ≤ 20 ng/mL (170, 41.9%) and > 20 ng/mL (236, 58.1%).

**Association between CASP8 -652 6N ins/del polymorphism and prostate cancer risk**

The genotype and allele frequencies of the CASP8 -652 6N ins/del polymorphism and prostate cancer risk

| Variables | Cases (n = 406) | Controls (n = 408) | P* |
|-----------|----------------|--------------------|----|
| Age (years) (mean±SD) | 69.4±6.6 | 69.3±5.5 | 0.916 |
| < 70 | 183 (45.1) | 202 (49.5) | 0.205 |
| ≥ 70 | 223 (54.9) | 206 (50.5) | |
| Smoking status | | | 0.001 |
| Never | 163 (40.2) | 205 (50.3) | |
| Ever | 243 (59.8) | 203 (49.7) | |
| Pack-years ≤ 28 | 110 (27.1) | 115 (28.2) | |
| Pack-years > 28 | 133 (32.7) | 88 (21.5) | |
| Alcohol drinking | | | 0.029 |
| Never | 294 (70.0) | 313 (76.7) | |
| Ever | 122 (30.0) | 95 (23.3) | |
| Family history of cancers | | < 0.001 |
| No | 291 (71.7) | 342 (83.3) | |
| Yes | 115 (28.3) | 66 (16.2) | |
| Clinical stage | | | |
| Localized | 218 (53.7) | | |
| Advanced | 188 (46.3) | | |
| Gleason (score) | | | |
| < 7 | 173 (42.6) | | |
| = 7 | 106 (26.1) | | |
| > 7 | 127 (31.3) | | |
| PSA (ng/mL) | | | |
| ≤ 20 | 170 (41.9) | | |
| > 20 | 236 (58.1) | | |

* t-test for age distributions between the cases and controls; two-sided \( \chi^2 \) test for the other selected variables between the cases and controls. PSA: prostate specific antigen.
-652 6N ins/del polymorphism in the cases and controls and their associations with prostate cancer risk are shown in Table 2. The observed genotype frequency among the control subjects was in agreement with the HWE ($\chi^2 = 1.01, P = 0.315$). The frequencies of the 6N ins/ins, ins/del, and del/del genotypes were 63.3%, 32.5%, and 4.2%, respectively, among the cases, and 51.7%, 39.0%, and 9.3%, respectively, among the controls ($P = 0.001$). The del allele frequencies were 0.20 among the cases and 0.29 among the controls ($P < 0.001$). As shown in Table 2, when we used the 6N ins/ins genotype as the reference, we found that both 6N ins/del and del/del genotypes were associated with a statistically significantly decreased risk of prostate cancer (adjusted OR = 0.68, 95% CI = 0.51-0.92 for 6N ins/del and adjusted OR = 0.34, 95% CI = 0.19-0.63 for 6N del/del). We also found that the risk of prostate cancer associated with the del allele was decreased in a dose-response manner ($P_{\text{trend}}$ = 0.001). In the stratification analysis, as shown in Table 3, we found that the decreased risk of prostate cancer was pronounced among subgroups of age $\geq$ 70 (CI = 0.47, 95%CI 0.31-0.69), smokers and non-drinkers (OR = 0.63, 95%CI = 0.46-0.88). As shown in Table 4, when the cases were stratified by clinicopathological characteristics (i.e., clinical stage, Gleason score and PSA level) and compared with the controls, we found that the associations were all statistically significant. However, when we used the localized clinical stage, Gleason < 7 and PSA $\leq$ 20 as control, we found no trends (data not shown).

Table 2 Genotype and allele frequencies of the CASP8 -652 6N ins/del polymorphism among cases and controls and their associations with risk of prostate cancer

| Genotypes   | Cases (n = 406) | Controls (n = 406) | Adjusted OR (95% CI) | $P^a$ |
|-------------|----------------|-------------------|----------------------|------|
| n (%)       | n (%)          |                   |                      |      |
| ins/ins 257 (63.3) | 211 (51.7) | 1.00              |                      |      |
| ins/del 132 (32.5) | 159 (39.0) | 0.68 (0.51-0.92) | 0.011                |      |
| del/del 17 (4.2) | 38 (9.3)  | 0.34 (0.19-0.63) | 0.001                |      |
| del allele 0.20 | 0.29     | < 0.001           |                      |      |

Adjusted for age, smoking and drinking status; $^a$Two-sided $\chi^2$ test. OR: odds ratio.

In the present study, 23 prostate cancer tissues were obtained from the untreated prostate cancer patients with different genotypes of the 6Nins/del polymorphism. We found that the frequency distribution of the 6N ins/ins, ins/del, del/del genotypes was 12, 10 and 1, respectively. Because only one sample with the del/del genotype was obtained, we added it to the samples with ins/del genotype for analysis. The associations between the two groups and CASP8 mRNA expression were performed by using qRT-PCR. As shown in Fig. 1, the level of CASP8 mRNA was lower in individuals with the del allele than in those with the 6N ins/ins genotype, and this difference was statistically significant (6N ins/ins vs 6N ins/del + del/del: 1.317±0.25 vs 1.000±0.28, $P = 0.024$, in arbitrary units).

**DISCUSSION**

In this study, we identified that the CASP8 -652 6N
Table 4 Associations between the CASP8 -652 6N ins/del polymorphism and clinicopathological characteristics of prostate cancer variables

| Variables                        | Genotype                | Adjusted OR (95% CI) | p* |
|----------------------------------|-------------------------|----------------------|----|
| Controls (n = 408)               | ins/ins [n (%)]         | ins/del + del/del [n (%)] |     |
| Cases (n = 406)                  | 211 (51.7)              | 197 (48.3)           | 1.00 |
| Clinical stage                   |                         |                      |     |
| Localized                        | 141 (64.7)              | 77 (35.3)            | 0.62 (0.47-0.82) | 0.001 |
| Advanced                         | 116 (61.7)              | 72 (38.3)            | 0.62 (0.45-0.85) | 0.023 |
| Gleason (score)                  |                         |                      |     |
| < 7                              | 106 (61.3)              | 67 (38.7)            | 0.67 (0.47-0.97) | 0.034 |
| ≥ 7                              | 71 (67.0)               | 35 (33.0)            | 0.50 (0.31-0.79) | 0.005 |
| PSA (ng/mL)                      | ≤ 20                    | 64 (37.6)            | 0.63 (0.44-0.91) | 0.017 |
|                                  | > 20                    | 151 (64.0)           | 0.61 (0.44-0.84) | 0.003 |

*Two-sided χ² test; † Adjusted for age, smoking and drinking status. CI: confidence interval; OR: odds ratio; PSA: prostate antigen.

Fig. 1 Association between the CASP8-652 6N ins/del polymorphism and mRNA levels. CASP8 mRNA transcript in prostate cancer tissues was assessed by quantitative real-time PCR. The frequency distributions of the 6N ins/ins, 6N ins/del, and 6N del/del genotypes were 12, 10, and 1, respectively. The fold change was normalized against GAPDH. †, P < 0.05 compared with 6N ins/ins genotype.

Apoptosis is an important and complicated process. Caspases are a conserved family of cysteine proteases that are responsible for cellular apoptosis. CASP8 is an essential regulator of apoptosis. The two common polymorphisms in the CASP8 gene, -652 6N ins/del and D302H, have been well studied. However, Frank et al. reported that the CASP8 -652 6N ins/del polymorphism was not associated with breast cancer in Europeans. Additionally, Pittman et al. failed to replicate this association with colorectal cancer risk. In a multiethnic cohort study, Haiman et al. revealed that a promoter polymorphism in the CASP8 gene was not associated with risk of breast cancer, colorectal cancer and prostate cancer. In the present study, we found that the CASP8 -652 6N ins/del polymorphism was associated with reduced risk of prostate cancer in a Chinese population. Meanwhile, we obtained the corresponding association between CASP8 mRNA expression and 6N ins/del polymorphism. The -652 6N del variant reduced CASP8 mRNA expression by removing a binding site for the transcriptional activator Sp1 in lymphocytes, and T lymphocytes with the del allele had lower CASP8 activity. Explanation of the discrepancy may be the differences in genetic backgrounds, study populations and study samples. The differences may reflect the fact that the association between the CASP8 -652 6N ins/del polymorphism and the decreased cancer risk is more dominant in Chinese populations. These may explain the low incidence of prostate cancer in China from some aspects.

To our best knowledge, age is an important risk factor of prostate cancer, and the incidence of prostate cancer has shown an increasing trend in elderly men. Tobacco smoking is shown to be significantly associated with higher lung cancer risk and moder-
ately increased all cancer risk\textsuperscript{[20]}. In a word, increasing age and tobacco smoking are risk factors for health. At the same time, moderate alcohol drinking is good for health\textsuperscript{[20]}. However, we found that the protective effect of the 6N del allele was more pronounced in subgroups of age \(\geq 70\) years, smokers, and non-drinkers. The probable interpretation of this discrepancy may be that when individuals are exposed to relative dangerous environmental factors, the protective effect of the 6N del allele becomes more dominant to protect individuals. Meanwhile, stratification analysis of clinicopathological characteristics showed that the associations were statistically significant when each subgroup was compared with controls, and the association between cases and controls was statistically significant (adjusted OR = 0.62, 95% CI = 0.47-0.82). However, there were no statistically significant trends when we used localized clinical stage, Gleason < 7 and PSA \(\leq 20\) ng/mL as control (data not shown).

Several limitations in this study should be addressed. Firstly, our study was a hospital-based case-control study, which could not evacuate the possibility of selection bias of subjects. However, the genotype distributions in our research are consistent with HWE (\(\chi^2 = 1.01, P = 0.315\)) and the results are similar to the published data in Chinese population\textsuperscript{[18,19]}. For instance, the frequencies of the ins/ins, ins/del, del/del genotypes among our controls were 51.7%, 39.0% and 9.3%, respectively, compared to 55.7%, 37.5% and 6.8% in the study by Wang \textit{et al.}\textsuperscript{[19]} and 56.3%, 37.2% and 6.5% in the study by Sun \textit{et al.}\textsuperscript{[10]}. Secondly, our study sample size was relatively small, which may limit the statistical power. Larger sample size studies are needed to validate these findings. Thirdly, only one sample with the del/del genotype was obtained among the 23 prostate cancer tissues; thus, we added it to the samples with the ins/del genotype for analysis. More samples of prostate cancer tissues are needed for more in-depth studies.

In conclusion, this study identified that the \textit{CASP8} -652 6N ins/del polymorphism was associated with reduced risk of prostate cancer in a Chinese population.

References

\begin{enumerate}
  \item Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. \textit{CA Cancer J Clin} 2009;59:225-49.
  \item Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. \textit{Eur J Cancer} 2005;41:334-45.
  \item Matsuda T, Saika K. Comparison of time trends in prostate cancer incidence (1973-1997) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vols IV VIII. \textit{Jpn J Clin Oncol} 2007;37:556-7.
  \item Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. \textit{CA Cancer J Clin} 2005;55:74-108.
  \item Matsuda T, Saika K. Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX. \textit{Jpn J Clin Oncol} 2009;39:465-9.
  \item Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. \textit{Cancer Epidemiol Biomarkers Prev} 2001;10:345-53.
  \item Chokkalingam AP, Stanczyk FZ, Reichardt JK, Hsing AW. Molecular epidemiology of prostate cancer: hormone-related genetic loci. \textit{Front Biosci} 2007;12:3436-60.
  \item Ntais C, Polycarpou A, Tsatsoulis A. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. \textit{Eur J Endocrinol} 2003;149:469-77.
  \item Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. \textit{Pharmacol Ther} 2001;92:57-70.
  \item de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. \textit{Nat Rev Cancer} 2006;6:24-37.
  \item Siegel RM. Caspases at the crossroads of immune-cell life and death. \textit{Nat Rev Immunol} 2006;6:308-17.
  \item Ho PK. Hawkins CJ. Mammalian initiator apoptotic caspases. \textit{Fests J 2005;27:525-53.
  \item Cox A, Dunning AM, Garcia-Closas M, Balsubramanian S, Reed MW, Pooley KA, \textit{et al.} A common coding variant in \textit{CASP8} is associated with breast cancer risk. \textit{Nat Genet} 2007;39:332-8.
  \item Vecchi GD, Verderio P, Pizzamiglio S, Manoukian S, Barile M, Fortuzzi S, \textit{et al.} Evidence for association of the \textit{CASP8} -652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases. \textit{Breast Cancer Res Treat} 2009;113:607-8.
  \item MacPherson G, Healey CS, Teare MD, Balsubramanian SP, Reed MW, Pharoah PH, \textit{et al.} Association of a common variant of the \textit{CASP8} gene with reduced risk of breast cancer. \textit{J Natl Cancer Inst} 2004;96:1866-9.
  \item Enjuanes A, Benavente Y, Bosch F, Martin-Guerrero I, Colomer D, Perez-Alvarez S, \textit{et al.} Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. \textit{Cancer Res} 2008;68:10178-86.
  \item Son JW, Kang HK, Chae MH, Choi JE, Park JM, Lee WK, \textit{et al.} Polymorphisms in the caspase-8 gene and the risk of lung cancer. \textit{Cancer Genet Cyto genet} 2006;169:121-7.
  \item Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, \textit{et al.} A six-nucleotide insertion-deletion polymorphism in the \textit{CASP8} promoter is associated with risk and progression of bladder
cancer. Clin Cancer Res 2009;15:2567-72.

[20] Frank B, Hemminki K, Wappenschmidt B, Meindl A, Klaes R, Schmutzler RK, et al. Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant. Carcinogenesis 2006;27:606-9.

[21] Lubahn J, Berndt SI, Jin CH, Klim A, Luly J, Wu WS, et al. Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. Prostate 2009;70:646-53.

[22] Haiman CA, Garcia RR, Kolonel LN, Henderson BE, Wu AH, Le Marchand L. A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat Genet 2008;40:259-60; author reply 60-1.

[23] Wang M, Zhang Z, Zhu H, Fu G, Wang S, Wu D, et al. A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population. Clin Cancer Res 2008;14:3633-40.

[24] Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.

[25] Frank B, Rigas SH, Bermejo JL, Wiestler M, Wagner K, Hemminki K, et al. The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res Treat 2008;111:139-44.

[26] Pittman AM, Broderick P, Sullivan K, Fielding S, Webb E, Penegar S, et al. CASP8 variants D302H and -652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population. Br J Cancer 2008;98:1434-6.

[27] Park S, Bae J, Nam BH, Yoo KY. Aetiology of cancer in Asia. Asian Pac J Cancer Prev 2008;9:371-90.

[28] Thorgerisson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008;452:638-42.

[29] Bondy SJ, Rehm J, Ashley MJ, Walsh G, Single E, Room R. Low-risk drinking guidelines: the scientific evidence. Can J Public Health 1999;90:264-70.